

Srinivasan Dasarathy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8030466/publications.pdf>

Version: 2024-02-01

143
papers

19,255
citations

25034

57
h-index

11939

134
g-index

153
all docs

153
docs citations

153
times ranked

25916
citing authors

#	ARTICLE	IF	CITATIONS
1	Macrophage-derived MLKL in alcohol-associated liver disease: Regulation of phagocytosis. <i>Hepatology</i> , 2023, 77, 902-919.	7.3	15
2	Hepatocellular Carcinoma in Patients Without Cirrhosis: The Fibrosis Stage Distribution, Characteristics and Survival. <i>Digestive Diseases and Sciences</i> , 2022, 67, 2677-2687.	2.3	4
3	Gut microbial trimethylamine is elevated in alcohol-associated hepatitis and contributes to ethanol-induced liver injury in mice. <i>ELife</i> , 2022, 11, .	6.0	21
4	Randomized placebo-controlled trial of losartan for pediatric NAFLD. <i>Hepatology</i> , 2022, 76, 429-444.	7.3	9
5	IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis. <i>Hepatology</i> , 2022, 76, 1058-1068.	7.3	41
6	Validation of the accuracy of the FAST score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms. <i>PLoS ONE</i> , 2022, 17, e0266859.	2.5	20
7	Acute skeletal muscle loss in SARS-CoV-2 infection contributes to poor clinical outcomes in COVID-19 patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 2436-2446.	7.3	17
8	Muscle loss contributes to higher morbidity and mortality in COPD: An analysis of national trends. <i>Respirology</i> , 2021, 26, 62-71.	2.3	26
9	Diagnostic and Prognostic Significance of Complement in Patients With Alcohol-Associated Hepatitis. <i>Hepatology</i> , 2021, 73, 983-997.	7.3	17
10	Activated Protein Phosphatase 2A Disrupts Nutrient Sensing Balance Between Mechanistic Target of Rapamycin Complex 1 and Adenosine Monophosphate-Activated Protein Kinase, Causing Sarcopenia in Alcohol-Associated Liver Disease. <i>Hepatology</i> , 2021, 73, 1892-1908.	7.3	17
11	Effect of Acid Suppressants on the Risk of COVID-19: A Propensity Score-Matched Study Using UK Biobank. <i>Gastroenterology</i> , 2021, 160, 455-458.e5.	1.3	31
12	Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression. <i>Metabolism: Clinical and Experimental</i> , 2021, 116, 154457.	3.4	62
13	Intestinal function is impaired in patients with Chronic Obstructive Pulmonary Disease. <i>Clinical Nutrition</i> , 2021, 40, 2270-2277.	5.0	23
14	Differential role of MLKL in alcohol-associated and non-alcohol-associated fatty liver diseases in mice and humans. <i>JCI Insight</i> , 2021, 6, .	5.0	27
15	Multimics-Identified Intervention to Restore Ethanol-Induced Dysregulated Proteostasis and Secondary Sarcopenia in Alcoholic Liver Disease. <i>Cellular Physiology and Biochemistry</i> , 2021, 55, 91-116.	1.6	24
16	Compound Sarcopenia in Hospitalized Patients with Cirrhosis Worsens Outcomes with Increasing Age. <i>Nutrients</i> , 2021, 13, 659.	4.1	17
17	Clinical impact of compound sarcopenia in hospitalized older adult patients with heart failure. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 1815-1825.	2.6	15
18	Quantitative Computed Tomography Assessment of Pectoralis and Erector Spinae Muscle Area and Disease Severity in Chronic Obstructive Pulmonary Disease Referred for Lung Volume Reduction. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2021, 18, 191-200.	1.6	10

#	ARTICLE	IF	CITATIONS
19	Acute Responses to Oxygen Delivery via High Flow Nasal Cannula in Patients with Severe Chronic Obstructive Pulmonary Disease—HFNC and Severe COPD. <i>Journal of Clinical Medicine</i> , 2021, 10, 1814.	2.4	5
20	Alcohol Consumption Is Associated with Poor Prognosis in Obese Patients with COVID-19: A Mendelian Randomization Study Using UK Biobank. <i>Nutrients</i> , 2021, 13, 1592.	4.1	16
21	Sarcopenia and frailty in decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 75, S147-S162.	3.7	145
22	Integrated multiomics analysis identifies molecular landscape perturbations during hyperammonemia in skeletal muscle and myotubes. <i>Journal of Biological Chemistry</i> , 2021, 297, 101023.	3.4	10
23	Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2021, 74, 1611-1644.	7.3	263
24	Hepatocellular carcinoma in nonalcoholic fatty liver disease with or without cirrhosis: a population-based study. <i>BMC Gastroenterology</i> , 2021, 21, 394.	2.0	32
25	Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. <i>New England Journal of Medicine</i> , 2021, 385, 1559-1569.	27.0	406
26	Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 2031.	7.4	141
27	Cardiac expression of microRNA-7 is associated with adverse cardiac remodeling. <i>Scientific Reports</i> , 2021, 11, 22018.	3.3	6
28	Metabolic reprogramming during hyperammonemia targets mitochondrial function and postmitotic senescence. <i>JCI Insight</i> , 2021, 6, .	5.0	17
29	Vitamin D deficiency: prevalence and association with liver disease severity in pediatric nonalcoholic fatty liver disease. <i>European Journal of Clinical Nutrition</i> , 2020, 74, 427-435.	2.9	17
30	Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2020, 72, 25-33.	3.7	88
31	Keratin 18 Is a Diagnostic and Prognostic Factor for Acute Alcoholic Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2046-2054.	4.4	52
32	Continued muscle loss increases mortality in cirrhosis: Impact of aetiology of liver disease. <i>Liver International</i> , 2020, 40, 1178-1188.	3.9	45
33	Myogenic Response to Increasing Concentrations of Ammonia Differs between Mammalian, Avian, and Fish Species: Cell Differentiation and Genetic Study. <i>Genes</i> , 2020, 11, 840.	2.4	5
34	Design and rationale of a multicenter defeat alcoholic steatohepatitis trial: (DASH) randomized clinical trial to treat alcohol-associated hepatitis. <i>Contemporary Clinical Trials</i> , 2020, 96, 106094.	1.8	16
35	Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000352.	2.7	30
36	ESPEN practical guideline: Clinical nutrition in liver disease. <i>Clinical Nutrition</i> , 2020, 39, 3533-3562.	5.0	170

#	ARTICLE	IF	CITATIONS
37	MLKL-dependent signaling regulates autophagic flux in a murine model of non-alcohol-associated fatty liver and steatohepatitis. <i>Journal of Hepatology</i> , 2020, 73, 616-627.	3.7	96
38	Exercise and physical activity in cirrhosis: opportunities or perils. <i>Journal of Applied Physiology</i> , 2020, 128, 1547-1567.	2.5	12
39	Ex-Vivo Normothermic Limb Perfusion With a Hemoglobin-Based Oxygen Carrier Perfusate. <i>Military Medicine</i> , 2020, 185, 110-120.	0.8	13
40	Plasma Krebs Cycle Intermediates in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 314.	2.4	9
41	Multicenter Validation of Association Between Decline in MRIâ€PDF and Histologic Response in NASH. <i>Hepatology</i> , 2020, 72, 1219-1229.	7.3	79
42	Comprehensive metabolic flux analysis to explain skeletal muscle weakness in COPD. <i>Clinical Nutrition</i> , 2020, 39, 3056-3065.	5.0	19
43	The Pathogenesis of Physical Frailty and Sarcopenia. , 2020, , 33-53.		1
44	Skeletal muscle loss phenotype in cirrhosis: A nationwide analysis of hospitalized patients. <i>Clinical Nutrition</i> , 2020, 39, 3711-3720.	5.0	13
45	EASL Clinical Practice Guidelines on nutrition in chronic liver disease. <i>Journal of Hepatology</i> , 2019, 70, 172-193.	3.7	608
46	HDL flux is higher in patients with nonalcoholic fatty liver disease. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019, 317, E852-E862.	3.5	26
47	Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. <i>JAMA Network Open</i> , 2019, 2, e1912565.	5.9	230
48	Oxidative stress mediates ethanol-induced skeletal muscle mitochondrial dysfunction and dysregulated protein synthesis and autophagy. <i>Free Radical Biology and Medicine</i> , 2019, 145, 284-299.	2.9	63
49	ESPEN guideline on clinical nutrition in liver disease. <i>Clinical Nutrition</i> , 2019, 38, 485-521.	5.0	387
50	Safety of Hyaluronan 35 in Healthy Human Subjects: A Pilot Study. <i>Nutrients</i> , 2019, 11, 1135.	4.1	8
51	A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation. <i>Hepatology</i> , 2019, 70, 1816-1829.	7.3	163
52	Impaired Ribosomal Biogenesis by Noncanonical Degradation of β -Catenin during Hyperammonemia. <i>Molecular and Cellular Biology</i> , 2019, 39, .	2.3	18
53	Ethanol sensitizes skeletal muscle to ammonia-induced molecular perturbations. <i>Journal of Biological Chemistry</i> , 2019, 294, 7231-7244.	3.4	31
54	Biomarkers of Macrophage Activation and Immune Danger Signals Predict Clinical Outcomes in Alcoholic Hepatitis. <i>Hepatology</i> , 2019, 70, 1134-1149.	7.3	66

#	ARTICLE	IF	CITATIONS
55	Ammonia Induces a Myostatin-Mediated Atrophy in Mammalian Myotubes, but Induces Hypertrophy in Avian Myotubes. <i>Frontiers in Sustainable Food Systems</i> , 2019, 3, .	3.9	3
56	Composite Vascularized Allograft Machine Preservation: State of the Art. <i>Current Transplantation Reports</i> , 2019, 6, 265-276.	2.0	6
57	Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. <i>American Journal of Gastroenterology</i> , 2019, 114, 1626-1635.	0.4	65
58	Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 156-163.e2.	4.4	322
59	Relationship between three commonly used noninvasive fibrosis biomarkers and improvement in fibrosis stage in patients with nonalcoholic steatohepatitis. <i>Liver International</i> , 2019, 39, 924-932.	3.9	47
60	Hyperammonemia and proteostasis in cirrhosis. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2018, 21, 30-36.	2.5	72
61	Poor performance of psoas muscle index for identification of patients with higher waitlist mortality risk in cirrhosis. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 1053-1062.	7.3	101
62	Patient and Caregiver Attitudes and Practices of Exercise in Candidates Listed for Liver Transplantation. <i>Digestive Diseases and Sciences</i> , 2018, 63, 3290-3296.	2.3	10
63	Hepatic Mitochondrial Defects in a Nonalcoholic Fatty Liver Disease Mouse Model Are Associated with Increased Degradation of Oxidative Phosphorylation Subunits. <i>Molecular and Cellular Proteomics</i> , 2018, 17, 2371-2386.	3.8	59
64	Bariatric Surgery in Patients with Cirrhosis and Portal Hypertension. <i>Obesity Surgery</i> , 2018, 28, 3431-3438.	2.1	34
65	Nutrition and the Liver. , 2018, , 837-843.e3.		0
66	A multicenter study to define sarcopenia in patients with end-stage liver disease. <i>Liver Transplantation</i> , 2017, 23, 625-633.	2.4	343
67	Reply to: "Myokines: a promising therapeutic target for hepatic encephalopathy". <i>Journal of Hepatology</i> , 2017, 66, 1100-1101.	3.7	0
68	Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis. <i>Hepatology</i> , 2017, 65, 2045-2058.	7.3	147
69	The TMAO-Producing Enzyme Flavin-Containing Monooxygenase 3 Regulates Obesity and the Being of White Adipose Tissue. <i>Cell Reports</i> , 2017, 19, 2451-2461.	6.4	194
70	Sarcopenia in Alcoholic Liver Disease: Clinical and Molecular Advances. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 1419-1431.	2.4	73
71	Are Exercise Benefits in Nonalcoholic Fatty Liver Disease Due to Increased Autophagy?. <i>Exercise and Sport Sciences Reviews</i> , 2017, 45, 125-125.	3.0	4
72	Alcoholic Liver Disease on the Rise: Interorgan Cross Talk Driving Liver Injury. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 880-882.	2.4	14

#	ARTICLE	IF	CITATIONS
73	Ammonia toxicity: from head to toe?. <i>Metabolic Brain Disease</i> , 2017, 32, 529-538.	2.9	166
74	In vitro contraction protects against palmitate-induced insulin resistance in C2C12 myotubes. <i>American Journal of Physiology - Cell Physiology</i> , 2017, 313, C575-C583.	4.6	31
75	Patients with Nonalcoholic Fatty Liver Disease Have a Low Response Rate to Vitamin D Supplementation. <i>Journal of Nutrition</i> , 2017, 147, 1938-1946.	2.9	26
76	Myostatin and beyond in cirrhosis: all roads lead to sarcopenia. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2017, 8, 864-869.	7.3	54
77	Interobserver Variability in Scoring Liver Biopsies with a Diagnosis of Alcoholic Hepatitis. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 1568-1573.	2.4	24
78	Ammonia elicits a different myogenic response in avian and murine myotubes. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2017, 53, 99-110.	1.5	9
79	Safety and efficacy of bariatric surgery in patients with advanced fibrosis. <i>International Journal of Obesity</i> , 2017, 41, 443-449.	3.4	21
80	Hyperammonemia results in reduced muscle function independent of muscle mass. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 310, G163-G170.	3.4	56
81	Nutrition and Alcoholic Liver Disease. <i>Clinics in Liver Disease</i> , 2016, 20, 535-550.	2.1	60
82	Sarcopenia from mechanism to diagnosis and treatment in liver disease. <i>Journal of Hepatology</i> , 2016, 65, 1232-1244.	3.7	436
83	Hyperammonaemia-induced skeletal muscle mitochondrial dysfunction results in cataplerosis and oxidative stress. <i>Journal of Physiology</i> , 2016, 594, 7341-7360.	2.9	122
84	Cause and management of muscle wasting in chronic liver disease. <i>Current Opinion in Gastroenterology</i> , 2016, 32, 1.	2.3	84
85	Metabolic adaptation of skeletal muscle to hyperammonemia drives the beneficial effects of l-leucine in cirrhosis. <i>Journal of Hepatology</i> , 2016, 65, 929-937.	3.7	96
86	The development of a non-invasive model to predict the presence of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 995-1000.	2.8	19
87	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	9.1	4,701
88	Clinical Impact of Alcohol-Related Cirrhosis in the Next Decade: Estimates Based on Current Epidemiological Trends in the United States. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 2085-2094.	2.4	70
89	Sarcopenia in non-alcoholic fatty liver disease: Targeting the real culprit?. <i>Journal of Hepatology</i> , 2015, 63, 309-311.	3.7	37
90	Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients. <i>BBA Clinical</i> , 2015, 3, 141-145.	4.1	53

#	ARTICLE	IF	CITATIONS
91	Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis. <i>Hepatology</i> , 2015, 61, 2018-2029.	7.3	179
92	Age Impacts Ability of Aspartate/Alanine Aminotransferase Ratio to Predict Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1825-1831.	2.3	18
93	The effect of hyperammonemia on myostatin and myogenic regulatory factor gene expression in broiler embryos. <i>Animal</i> , 2015, 9, 992-999.	3.3	13
94	Double-blind Randomized Placebo-controlled Clinical Trial of Omega 3 Fatty Acids for the Treatment of Diabetic Patients With Nonalcoholic Steatohepatitis. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 137-144.	2.2	138
95	Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease. <i>Liver International</i> , 2015, 35, 979-985.	3.9	87
96	Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. <i>Lancet</i> , The, 2015, 385, 956-965.	13.7	1,840
97	Alcohol-induced autophagy contributes to loss in skeletal muscle mass. <i>Autophagy</i> , 2014, 10, 677-690.	9.1	121
98	Hypovitaminosis D is associated with increased whole body fat mass and greater severity of non-alcoholic fatty liver disease. <i>Liver International</i> , 2014, 34, e118-27.	3.9	94
99	Post-liver transplantation sarcopenia in cirrhosis: A prospective evaluation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1250-1257.	2.8	151
100	Presence of sarcopenia (muscle wasting) in patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2014, 60, 428-429.	7.3	36
101	Treatment to Improve Nutrition and Functional Capacity Evaluation in Liver Transplant Candidates. <i>Current Treatment Options in Gastroenterology</i> , 2014, 12, 242-255.	0.8	21
102	Is the adiponectin-AMPK-mitochondrial axis involved in progression of nonalcoholic fatty liver disease?. <i>Hepatology</i> , 2014, 60, 22-25.	7.3	26
103	Posttransplant Sarcopenia: An Underrecognized Early Consequence of Liver Transplantation. <i>Digestive Diseases and Sciences</i> , 2013, 58, 3103-3111.	2.3	92
104	Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 85-93.	1.6	168
105	Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF- κ B-mediated mechanism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 18162-18167.	7.1	211
106	Sarcopenia and a physiologically low respiratory quotient in patients with cirrhosis: a prospective controlled study. <i>Journal of Applied Physiology</i> , 2013, 114, 559-565.	2.5	59
107	Ethanol induces skeletal muscle autophagy and sarcopenia by an AMPK independent, PI3K dependent mechanism. <i>FASEB Journal</i> , 2013, 27, 713.8.	0.5	0
108	Handheld Calorimeter Is a Valid Instrument to Quantify Resting Energy Expenditure in Hospitalized Cirrhotic Patients. <i>Nutrition in Clinical Practice</i> , 2012, 27, 677-688.	2.4	28

#	ARTICLE	IF	CITATIONS
109	Consilience in sarcopenia of cirrhosis. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2012, 3, 225-237.	7.3	203
110	Hyperammonemia-mediated autophagy in skeletal muscle contributes to sarcopenia of cirrhosis. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2012, 303, E983-E993.	3.5	157
111	Malnutrition in Cirrhosis: Contribution and Consequences of Sarcopenia on Metabolic and Clinical Responses. <i>Clinics in Liver Disease</i> , 2012, 16, 95-131.	2.1	199
112	Late evening snack: Exploiting a period of anabolic opportunity in cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 430-441.	2.8	194
113	Prevalence of Hypothyroidism in Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2012, 57, 528-534.	2.3	140
114	Do Handheld Calorimeters Have a Role in Assessment of Nutrition Needs in Hospitalized Patients?. <i>Nutrition in Clinical Practice</i> , 2011, 26, 426-433.	2.4	52
115	Sarcopenia associated with portosystemic shunting is reversed by follistatin. <i>Journal of Hepatology</i> , 2011, 54, 915-921.	3.7	93
116	Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 382-388.	1.6	112
117	Changes in body composition after transjugular intrahepatic portosystemic stent in cirrhosis: a critical review of literature. <i>Liver International</i> , 2011, 31, 1250-1258.	3.9	65
118	Diagnosis and management of alcoholic liver disease. <i>Journal of Digestive Diseases</i> , 2011, 12, 257-262.	1.5	42
119	Plasma metabolomic profile in nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2011, 60, 404-413.	3.4	433
120	Metabolic and Genomic Response to Dietary Isocaloric Protein Restriction in the Rat. <i>Journal of Biological Chemistry</i> , 2011, 286, 5266-5277.	3.4	64
121	Alteration in body composition in the portacaval anastomosis rat is mediated by increased expression of myostatin. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 301, G731-G738.	3.4	16
122	Alcoholic liver disease. <i>Hepatology</i> , 2010, 51, 307-328.	7.3	981
123	Reply: Comments on AASLD practice guidelines for alcoholic liver disease. <i>Hepatology</i> , 2010, 51, 1861-1861.	7.3	24
124	Alcoholic Liver Disease. <i>American Journal of Gastroenterology</i> , 2010, 105, 14-32.	0.4	220
125	Malnutrition and Nutrition in Liver Disease. , 2010, , 1187-1207.		0
126	Glycine and urea kinetics in nonalcoholic steatohepatitis in human: effect of intralipid infusion. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 297, G567-G575.	3.4	42

#	ARTICLE	IF	CITATIONS
127	Posttransplant metabolic syndrome: An epidemic waiting to happen. <i>Liver Transplantation</i> , 2009, 15, 1662-1670.	2.4	143
128	Validity of real time ultrasound in the diagnosis of hepatic steatosis: A prospective study. <i>Journal of Hepatology</i> , 2009, 51, 1061-1067.	3.7	497
129	Inflammation and Liver. <i>Journal of Parenteral and Enteral Nutrition</i> , 2008, 32, 660-666.	2.6	18
130	Identificaition of Nonâ€Alcoholic Steatohepatitis (NASH) Using Plasma Metabolome in Humans. <i>FASEB Journal</i> , 2008, 22, 1162.5.	0.5	0
131	Altered expression of genes regulating skeletal muscle mass in the portacaval anastomosis rat. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 292, G1105-G1113.	3.4	57
132	Inhibition of aromatase improves nutritional status following portacaval anastomosis in male rats. <i>Journal of Hepatology</i> , 2006, 45, 214-220.	3.7	25
133	Skeletal muscle atrophy is associated with an increased expression of myostatin and impaired satellite cell function in the portacaval anastomosis rat. <i>American Journal of Physiology - Renal Physiology</i> , 2004, 287, G1124-G1130.	3.4	93
134	Role of Fresh Frozen Plasma Infusion in Correction of Coagulopathy of Chronic Liver Disease: A Dual Phase Study. <i>American Journal of Gastroenterology</i> , 2003, 98, 1391-1394.	0.4	162
135	Role of gut bacteria in the therapy of hepatic encephalopathy with lactulose and antibiotics. <i>Indian Journal of Gastroenterology</i> , 2003, 22 Suppl 2, S50-3.	1.4	2
136	Preservation of portal pressure improves growth and metabolic profile in the male portacaval-shunted rat. <i>Digestive Diseases and Sciences</i> , 2002, 47, 1936-1942.	2.3	18
137	Hepatic encephalopathy. <i>Current Treatment Options in Gastroenterology</i> , 2001, 4, 517-526.	0.8	13
138	Benzodiazepines in hepatic encephalopathy: sleeping with the enemy. <i>Gut</i> , 1998, 42, 764-765.	12.1	14
139	Fulminant hepatitis in a tropical population: Clinical course, cause, and early predictors of outcome. <i>Hepatology</i> , 1996, 23, 1448-1455.	7.3	244
140	Sonographic signs in portal hypertension: a multivariate analysis. <i>Tropical Gastroenterology: Official Journal of the Digestive Diseases Foundation</i> , 1996, 17, 23-9.	0.0	3
141	Sodium benzoate in the treatment of acute hepatic encephalopathy: A double-blind randomized trial. <i>Hepatology</i> , 1992, 16, 138-144.	7.3	177
142	Gallbladder Abnormalities in Acute Viral Hepatitis. <i>Journal of Clinical Gastroenterology</i> , 1991, 13, 697-700.	2.2	22
143	Gallstone Disease in North India. <i>Journal of Clinical Gastroenterology</i> , 1990, 12, 547-549.	2.2	11